1. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Issue 10326 (19th February 2022) Authors: Heier, Jeffrey S; Khanani, Arshad M; Quezada Ruiz, Carlos; Basu, Karen; Ferrone, Philip J; Brittain, Christopher; Figueroa, Marta S; Lin, Hugh; Holz, Frank G; Patel, Vaibhavi; Lai, Timothy Y Y; Silverman, David; Regillo, Carl; Swaminathan, Balakumar; Viola, Francesco; Cheung, Chui Ming Gemmy; Won... Journal: Lancet Issue: Volume 399:Issue 10326(2022) Page Start: 729 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Issue 10326 (19th February 2022) Authors: Wykoff, Charles C; Abreu, Francis; Adamis, Anthony P; Basu, Karen; Eichenbaum, David A; Haskova, Zdenka; Lin, Hugh; Loewenstein, Anat; Mohan, Shaun; Pearce, Ian A; Sakamoto, Taiji; Schlottmann, Patricio G; Silverman, David; Sun, Jennifer K; Wells, John A; Willis, Jeffrey R; Tadayoni, Ramin; Aaber... Journal: Lancet Issue: Volume 399:Issue 10326(2022) Page Start: 741 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗